Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
Le pentadcapeptide exerce son effet par le biais du processus d'angiogense (formation de vaisseaux sanguins)
The bpc-157 ghk-cu combination leverages BPC-157s systemic healing and GHK-Cus localized tissue remodeling capabilities
These studies revealed that these peptides had similar potency and maximal response in cells co-expressing CTR and RAMP3 (Supplementary Fig
D.YouJ.ParkK.AllenC
MECHANISM CATEGORIES RESEARCH CONDITIONS SAFETY Side effects Limited human safety data Animal toxicology shows wide therapeutic window Injection-site reactions reported anecdotally Known interactions Anticoagulants (theoretical, due to angiogenic activity unstudied) Contraindications Active malignancy (theoretical, due to angiogenic mechanism) Pregnancy/lactation (unstudied) REGULATORY STATUS FDA Placed on FDA Category 2 of the 503A bulks list (September 2023 update), barring compounding pharmacies from preparing it under section 503A
